Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals reported its Q3 FY2026 highlights, positioning itself as a specialist in next-generation synthetic anti-infectives with expanding global intellectual property and clinical programs. The company secured a AUD 5.3 million R&D tax incentive rebate for FY2025, strengthening its funding base as it advances late-stage clinical and collaborative development.
A second Cooperative Research and Development Agreement was signed with the U.S. Army Institute of Surgical Research to evaluate RECCE 327 Gel in a validated burn wound infection model targeting MRSA and Pseudomonas aeruginosa. While the CRADA carries no direct revenue or funding, it is strategically significant, enhancing Recce’s access to top-tier U.S. military research capabilities and potentially supporting future regulatory submissions, partnering and commercialisation.
Recce also advanced its international clinical footprint, with dosing continuing in its Phase 3 trial for diabetic foot infections in Indonesia, where market approval is anticipated in 2026. In parallel, a newly granted Brazilian patent for its anti-infectives, extending protection to 2041 and bringing its Family 4 patents to seven jurisdictions, further consolidates its global IP portfolio and underpins long-term commercial prospects.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australian-listed biotechnology company developing a new class of synthetic anti-infective drugs and formulations. Its lead candidates, including RECCE 327 in gel form, target serious infections such as burn wound pathogens and diabetic foot infections, with a focus on both civilian healthcare and military/Department of Defense-related applications across global markets.
Average Trading Volume: 89,392
Technical Sentiment Signal: Buy
Current Market Cap: A$151.8M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.